Molecular Formula | C25H39ClN4O3 |
Molar Mass | 479.05516 |
Storage Condition | 2-8℃ |
Target | PRMT6 |
In vitro study | In human melanoma A375 cells exogenously overexpressing PRMT6, EPZ020411 dose-dependently reduced H3R2 methylation (IC50=0.637±0.241 μm). In biochemical assays, EPZ020411 was more selective for PRMT6/8/1 than for other histone methyltransferases (including 4 arginine methyltransferases PRMT3, PRMT4, PRMT5, PRMT7) more than 100 times higher. In the parallel artificial membrane permeation test, EPZ020411 has poor permeability. |
In vivo study | EPZ020411 has good bioavailability by subcutaneous injection in rats and is a suitable compound for in vivo studies. A single intravenous injection of 1 mg/kg EPZ020411 into male Sprague-Dawley rats resulted in an in vivo clearance (CL) of 19.7±1.0 mL/min/kg and a volume of distribution (Vss) at steady state was 11.1±1.6 L/kg with an average half-life of 8.54±1.43 h. With subcutaneous injection of 5 mg/kg, with good bioavailability 65.6±4.3%, the free concentration of EPZ020411 in the blood was higher than the biochemical IC50 value of PRMT6 for more than 12 hours. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.087 ml | 10.437 ml | 20.874 ml |
5 mM | 0.417 ml | 2.087 ml | 4.175 ml |
10 mM | 0.209 ml | 1.044 ml | 2.087 ml |
5 mM | 0.042 ml | 0.209 ml | 0.417 ml |